NetworkNewsBreaks – CytoDyn Inc. (CYDY) Interim CMO to Present at 11th Annual Conference on Stem Cell and Regenerative Medicine

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence demonstrating the effectiveness of PRO 140 (leronlimab), which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines and block human breast cancer cell invasion.

To view the full press release, visit http://nnw.fm/SgzM0

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com

More from NetworkNewsBreaks

NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Adds Taxation Reporting Technology to its Proprietary Compliance Platform NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Announces Results of Independent Studies Supporting Restart of Canadian Refinery NetworkNewsBreaks – The Flowr Corporation (TSX.V: FLWR) Ships Initial Purchase Order from the NSLC

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.

Latest News

China bars millions from travel for 'social credit' offenses

Feb 24, 2019

BEIJING — Forgot to pay a fine in China? Then forget about buying an airline ticket. Would-be air travelers were blocked from buying tickets 17.5 million times last year under a controversial "social credit" system the ruling Communist Party says will improve public behavior. Some 5.5 million people were barred from buying train tickets, according to the National Public Credit Information Center. In an annual report, it said 128 people were blocked from leaving China because they were behind on their taxes. The ruling party says penalties and rewards under "social credit" will improve order in a fast-changing society. Three...

Report: US company to stop sales of genetic tech in Xinjiang

Feb 24, 2019

BEIJING — Thermo Fisher Scientific Inc. says it will no longer sell or service genetic sequencers in China's mostly Muslim region of Xinjiang following criticism that they were used for surveillance that enabled human rights abuses, The Wall Street Journal reported. The company in Waltham, Massachusetts, cited its "values, ethics code and policies," according to the Journal. The company said it recognized the importance of considering how products "are used — or may be used — by our customers." Thermo Fisher faced criticism from human rights groups and American lawmakers for supplying the equipment used to identify individuals in Xinjiang....

Exposed Chinese database shows depth of surveillance state

Feb 24, 2019

BEIJING — The Chinese database Victor Gevers found online was not just a collection of old personal details. It was a compilation of real-time data on more than 2.5 million people in western China, updated constantly with GPS coordinates of their precise whereabouts. Alongside their names, birthdates and places of employment, there were notes on the places that they had most recently visited — mosque, hotel, restaurant. The discovery by Gevers, a Dutch cybersecurity researcher who revealed it on Twitter last week, has given a rare glimpse into China's extensive surveillance of Xinjiang, a remote region home to an ethnic...

China accuses US of trying to block its tech development

Feb 24, 2019

BEIJING — China's government on Monday accused the United States of trying to block its industrial development after Vice President Mike Pence said Chinese equipment poses a threat to countries that are rolling out next-generation mobile communications. And in a potential blow to U.S. efforts to rally its allies on the issue, British media reported U.K. intelligence agencies found it is possible to limit potential security risks of Chinese equipment in fifth-generation networks. The U.S. argues Beijing might use Chinese tech companies to gather intelligence about foreign countries. The Trump administration has pressured allies to shun networks supplied by Huawei...

Australia blames 'state actor' for hacking political parties

Feb 24, 2019

CANBERRA, Australia — A "sophisticated state actor" was behind a cyberattack on the Australian Parliament's computing network that also affected the network used by major political parties, the prime minister said Monday. Prime Minister Scott Morrison did not identify the state behind what he described as a "malicious intrusion" on Feb. 8. A joint statement from House of Representatives Speaker Tony Smith and Senate President Scott Ryan said at the time that there was no evidence that data had been accessed in the breach. But lawmakers were advised to change passwords. Morrison revealed Monday that the computer networks used by...

Sign up now!